PracticeUpdate: Conference Series - EHA 2018

First page Table of contents Next page Last page

Neither Myeloablative nor Reduced-Intensity Conditioning Impact Overall Survival in T-Cell Lymphoma	3
Tisagenlecleucel Improves Quality of Life for Young Patients with Refractory B-Cell Acute Lymphoblastic Leukemia	4
Consider Obinutuzumab Plus Chlorambucil for First-Line Treatment for CLL	4
Low-Dose Heparin May Be Warranted in Patients Undergoing Lower Limb Surgical Revascularization	6
CLL1-CD33 cCAR T-cell Therapy Promising for AML	7
Erythropoietin Treatment More Effective in Myelofibrosis Patients with Anemia and V617F JAK2 Mutations	8
Nilotinib and Lower-Intensity Chemotherapy Promising Treatment for Ph+ Acute Lymphoblastic Leukemia	9
Consider Interventions to Reduce Weight in Patients With Myeloproliferative Neoplasms	10
EUTOS Long-Term Survival Score Superior for Prognosis of Survival in CML	11
Consider Ibrutinib-Rituximab (IR) as Standard Therapeutic Option for Waldenstrom’s Macroglobulinemia	12
Use of Ruxolitinib–Hydroxyurea Benefits Patients with Myelofibrosis	13
Response Rates Improve Significantly With Three-Drug Combination for DLBCL	14
Rituximab Yields Durable Response in Adults With Persistent or Chronic Immune Thrombocytopenia	14

Made with FlippingBook - Online magazine maker